Michael B. Lawing, Director of Outreach, KCCure has been selected to participate in the Scientist <-> Survivor Program at the 11th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved Nov. 2-5, 2018 in New Orleans, LA.
The conference will address all levels of basic, population, clinical, and transdisciplinary research related to cancer and will bring together physicians, scientists, health professionals, and health care leaders working in a variety of disciplines to discuss the latest findings in their fields.
Patient Advocates attending the meeting will communicate to scientists the key issues, questions, and concerns of the survivor and patient advocacy communities; and network with scientists and fellow advocates from local, national, and international cancer organizations.
Lawing, a longtime alumnus of the Scientist<->Survivor Program at the AACR’s Annual Meeting has been a member of the AACR since 2010 and will be presenting information on Making Strides Against a Rare Disease: Renal Medullary Carcinoma (RMC) in the general poster session. In conjunction with our partner organization RMC Support, KCCure has been active in helping to increase awareness about this rare and aggressive form of kidney cancer.
The American Association for Cancer Research (AACR) the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.
The Kidney Cancer Research Alliance (KCCure) is a grassroots organization of patients, caregivers, doctors and medical researchers dedicated to eliminating suffering and death due to kidney cancer through increased funding to accelerate research that will lead to a cure for all patients and prevent future kidney cancer diagnoses.